Under the terms of the agreement Neurobiological Technologies will exclusively license certain patent rights related to a naturally occurring protein that has been shown in animals to reverse the symptoms of Alzheimer’s disease. As part of this agreement, Neurobiological Technologies has agreed to fund a joint research collaboration with the Buck relating to the Alzheimer’s drug development for up to three years. Research funding for the initial year under the agreement will total $1.2 million.
In consideration for the license, Neurobiological Technologies will pay upfront license fees totaling $175,000 over a three-year period. This agreement is the second collaboration between Neurobiological Technologies and Buck focused on central nervous system conditions.
Paul Freiman, president and CEO of Neurobiological Technologies, said: “The partnership with the Buck Institute has the potential to expand our pipeline of product candidates in central nervous system disorders.”